Global contract packaging organization, Tjoapack, has signed a five-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products.
Hexvix/Cysview is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix/Cysview improves the detection of tumors and leads to more complete resection, less residual tumors and better management decisions.
The contract will see Tjoapack perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
“We’re delighted to be working with a company like Photocure who’s technology can make such a difference to patients,” Dexter Tjoa, Director Corporate Strategy at Tjoapack said. “Photocure has a global customer base, which comes with many potential challenges. At Tjoapack, we have a huge amount of experience in meeting the demands of multiple markets, especially when it comes to complying with legislation, such as artwork requirements and serialization.
During the project, Tjoapack will be working with semi-finished stock stored at its facility, only finalizing and assembling kits when orders come in.
“Photocure delivers transformative solutions to improve the lives of bladder cancer patients. This is very much in line with Tjoapack’s ethos which was a big decision-making factor for us when choosing a partner,” Gry Stensrud, VP of Technical Development & Operations, at Photocure said. “We were also specifically looking for a supplier who was ready for serialization. While our product does not need to be serialized in the US as imaging drugs are exempt there, compliance with the EU FMD is vital in order to ensure continuous supply to our European markets. We were impressed by Tjoapack’s expertise in this area and are confident they’ll be able to meet our requirements.”